Indexado en

Licencia y uso

Citaciones

Altmetrics

Análisis de autorías institucional

Compartir

CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes

Publicado en:Cardiovascular Diabetology. 2025; 24 (1): - - 2025-12-01 24(1), DOI: 10.1186/s12933-025-02700-0

Autores: Schnell O; Almandoz J; Anderson L; Barnard-Kelly K; Battelino T; Blüher M; Busetto L; Catrinou D; Ceriello A; Cos X; Danne T; Dayan CM; Del Prato S; Fernández-Fernández B; Fioretto P; Forst T; Gavin JR; Giorgino F; Groop PH; Harsch IA; Heerspink HJL; Heinemann L; Ibrahim M; Jadoul M; Jarvis S; Ji L; Kanumilli N; Kosiborod M; Landmesser U; Macieira S; Mankovsky B; Marx N; Mathieu C; McGowan B; Milenkovic T; Moser O; Müller-Wieland D; Papanas N; Patel DC; Pfeiffer AFH; Rahelić D; Rodbard HW; Rydén L; Schaeffner E; Spearman CW; Stirban A; Tacke F; Topsever P; Van Gaal L; Standl E

Afiliaciones

Resumen

The 10th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on December 5–6, 2024. This year, discussions about cardiovascular (CV) and kidney outcome trials centered on the recent findings from studies involving empagliflozin (EMPACT-MI), semaglutide (STEP-HFpEF-DM and FLOW), tirzepatide (SURMOUNT-OSA and SUMMIT), and finerenone (FINEARTS-HF). These studies represent significant advances in reducing the risk of major adverse cardiovascular events (MACE) and improving metabolic outcomes in heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (CKD), and obstructive sleep apnea (OSA). The congress also comprised sessions on novel and established therapies for managing HFpEF, CKD, and obesity; guidelines for managing CKD and metabolic dysfunction-associated steatotic liver disease (MASLD); organ crosstalk and the development of cardio-kidney-metabolic (CKM) syndrome; precision medicine and person-centered management of diabetes, obesity, cardiovascular disease (CVD) and CKD; early detection of type 1 diabetes (T1D) and strategies to delay its onset; continuous glucose monitoring (CGM) and automated insulin delivery (AID); cardiovascular autonomic neuropathy (CAN) and the diabetic heart; and the role of primary care in the early detection, prevention and management of CKM diseases. The contribution of environmental plastic pollution to CVD risk, the increasing understanding of the efficacy and safety of incretin therapies in the treatment of CKM diseases, and the latest updates on nutrition strategies for CKM management under incretin-based therapies were also topics of interest for a vast audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians, who actively engaged in online discussions. The 11th CVOT Summit will be held virtually on November 20–21, 2025 (http://www.cvot.org).

Palabras clave